Vitiligo

A new population-based study demonstrates an association between patients having systemic sclerosis and vitiligo, suggesting both conditions may need to be monitored for comorbidities.

New research indicated that topical 5 FU for patients with vitiligo may be an option that is both a promising and cost-effective treatment for the skin condition.

A recent study into autoimmune and metabolic disturbances identified an association between these conditions and vitiligo cases.

Only 7% of trials included a patient-reported outcome measure as a primary outcome measure.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.

A 1-unit increase in mean weekly SPD scores was linked to a 1.4-times increase in clinic visits for itch among adults aged 65 years or old.

New research demonstrated a correlation between specific VDR polymorphisms and patients’ liability of having vitiligo.

A discussion with Dr. Lal on the topics of benefits of ruxolitinib treatment for nonsegmental vitiligo, as well as on the recent recall of hair products due to benzene risk.

Experts in dermatology review how JAK inhibitors will impact dermatology care across the board.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, consider how new advances in oral medication will impact physicians’ and patients’ decision-making when it comes to treatment of alopecia areata, vitiligo, and atopic dermatitis.

Dermatology experts discuss clinical specifics of JAK [Janus kinase] inhibitors and their impact on the treatment of patients with vitiligo and alopecia areata.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, discuss the use of topical JAK inhibitors in alopecia areata, vitiligo, and atopic dermatitis.

Brett King, MD, PhD, shares insight on the dosage efficacy of oral JAK inhibitors abrocitinib and upadacitinib in atopic dermatitis.

A study finds delayed puberty, a comorbidity of epidermolysis bullosa, may affect skeletal health.

The FDA recently approved a drug treatment for prurigo nodularis, studied across over 60 clinical trials.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, explore how severity of disease factors into treatment selection regarding the use of JAK inhibitors.

Drs Jerry Bagel and Brett King discuss safety considerations and the clinical impact of how boxed warnings for JAK inhibitors highlighting how they affect physician decision-making.

The investigators identified Osteoprotegerin in the serum of dupilumab treated patients, which could act as a predictor for clinical outcomes of dupilumab treatment.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

A discussion on the positive outcomes of acupuncture for Parkinson’s patients struggling with the effects of anxiety.

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.

The majority of patients treated with systemic therapies were treated with dupilumab, while 3.2% patients received a combination of systemic therapies.

Research suggests that tildrakizumab may be useful in real-life settings against moderate-to-severe plaque psoriasis.

Experts in dermatology review currently available JAK inhibitors for use in patients with dermatological conditions and highlight their differences.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, provide an overview of JAK inhibitors and their mechanisms of action in dermatology care.

Large numbers of vitiligo patients around the world have reported differing outcomes, with darker skin types expressing the more significant severity, according to new findings.

Research presented at EADV 2022 sees positive outcomes with the targeted therapy for patients of varied backgrounds with vitiligo.

Nonsegmental vitiligo not only affects the skin but can destroy melanocytes in other areas of the body including the eye, new research shows.

Patients over 21 years who developed acne presented with different clinical characteristics than younger patients.